# Vida Ventures

> Vida Ventures is a VC fund in Boston backing Biotechnology and Health Care. See 70 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 70
- Last investment: Jun 2026
- Lead investor: 33%
- Fund size: $825M
- Last fund: Jun 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/vida-ventures-llc/
- X (Twitter): https://twitter.com/Vida_Ventures
- Website: http://vidaventures.com/

Vida Ventures is a VC fund in Boston focused on Biotechnology and Health Care. Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .

## Contacts

5 contacts available for Vida Ventures. Shizune tracks 9 team members at Vida Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/vida-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $35M–$310M |
| Series B | $60M–$175M |
| Series C | $60M–$175M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 40 | 57% |
| Health Care | 24 | 34% |
| Medical | 19 | 27% |
| Therapeutics | 18 | 26% |
| Pharmaceutical | 13 | 19% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 23 | 33% |
| Series B | 17 | 24% |
| Series C | 9 | 13% |
| Seed | 6 | 9% |
| Series D | 2 | 3% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 40 | 57% |
| China | 1 | 1% |
| India | 1 | 1% |
| France | 1 | 1% |
| Denmark | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Fred Cohen | Co-Founder & Sr. Managing Director | 12 | https://shizune.co/investors/profile/fred-cohen |
| Helen Kim | Senior Managing Director | 8 | https://shizune.co/investors/profile/helen-s-kim-1469 |
| Mark Springel | Associate | 0 | https://shizune.co/investors/profile/mark-springel |
| Arie Belldegrun | Co-Founder & Senior Managing Director; Founding Partner | 5 | https://shizune.co/investors/profile/arie-belldegrun |
| Arjun Goyal | Co-Founder and Managing Director | 12 | https://shizune.co/investors/profile/arjun-goyal |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SonoThera | SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M | Series B | Jun 10, 2026 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M | Series C | Apr 14, 2026 |  |
| Poplar Therapeutics | Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis. | $50M | Series A | Jan 07, 2026 |  |
| Protego Biopharma | Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M | Series B | Dec 01, 2025 |  |
| Protego Biopharma | Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M | Series B | Dec 01, 2025 |  |
| Avalyn Pharma | Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $100M | Series D | Jul 22, 2025 |  |
| Antares Therapeutics | Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M | Series A | May 15, 2025 |  |
| Attovia Therapeutics | Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $90M | Series C | Apr 15, 2025 |  |
| Soufflé Therapeutics | Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $200M | Series A | Jan 01, 2025 |  |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $370M | Series B | Sep 09, 2024 |  |

10 of 70 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 18 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 13 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 13 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 12 deals together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 12 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 11 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)

## FAQ

### What does Vida Ventures invest in?

Vida Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 70 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Vida Ventures's check size?

Vida Ventures typically joins rounds of $35M–$310M at Series A, $60M–$175M at Series B and $60M–$175M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vida Ventures participates in.

### How do I contact Vida Ventures?

Public channels for Vida Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Vida Ventures?

The team at Vida Ventures includes Fred Cohen (Co-Founder & Sr. Managing Director), Helen Kim (Senior Managing Director) and Mark Springel (Associate), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co